

When sleep disturbance compounds depression . . .



# Sinequan<sup>\*</sup>

brand of doxepin

\* Trade Mark

settles the mind for sleep while treating the underlying depression.

▶ Sedative tricyclic antidepressant.

▶ Once nightly dosage.

**Indications:** depression with or without anxiety. **Contraindications:** glaucoma, urinary retention, hypersensitivity to the drug.

**Side effects:** dry mouth and drowsiness are most commonly reported. **Precautions:** Sinequan may potentiate other compounds - e.g. monoamine oxidase inhibitors; not recommended in pregnancy or children under 12 years of age.

**Dosage:** range 30mg to 300mg daily in divided doses; up to 100mg may be given as a single dose at night. **Packs and Basic N.H.S. Cost:** 10mg capsules (PL 57/5032), pack of 100, £2.66; 25mg capsules (PL 57/5033), pack of 100, £3.78; 50mg capsules (PL 57/5034), pack of 100, £6.26; 75mg capsules (PL 57/0133), pack of 60, £5.92.

Full information is available on request to the Company.

**Pfizer** PFIZER LIMITED, SANDWICH, KENT.

1850c

**baclofen INN**

# **Multiple Sclerosis Spinal Lesions**

**Also indicated for**

# **Spasticity associated with cerebral palsy**

**C I B A**

**References**

- 1 *Practical Therapeutics* (1975) 10, 112.
- 2 *Postgraduate Medical Journal* (1975) 51, 615

® denotes registered trademark.  
Full prescribing information is available on  
request from:  
CIBA Laboratories, Horsham, West Sussex,  
BN18 3UB

# New Madopar 62.5 in Parkinson's Disease Precision is the point.

Madopar has already changed the outlook of many patients with Parkinson's disease. The introduction of a new low-strength capsule, Madopar 62.5, offers an opportunity for others to benefit too. Some patients, especially the elderly, are very sensitive to the effects of Madopar and may find the usual starting dose of Madopar 125 simply too much to take. Others on long-term therapy experience fluctuations in performance which may be helped by administration of smaller, more frequent doses.<sup>2,3</sup> For these and other patients whose problems are dose-related the extra precision of Madopar 62.5 may well be the answer.



#### Presentation

Madopar contains a combination of levodopa and the decarboxylase inhibitor benserazide in the ratio of 4:1. Madopar 62.5 capsules containing 50mg levodopa. Madopar 125 capsules containing 100mg levodopa. Madopar 250 capsules containing 200mg levodopa.

#### Indications

Parkinsonism - idiopathic, post-encephalitic, arteriosclerotic.

#### Dosage

Dosage is variable and the data sheet should be consulted for full details. The effective daily dose usually lies between four and eight capsules of Madopar 125 (two to four capsules of Madopar 250) daily in divided doses, most patients requiring no more than six capsules of Madopar 125 daily. In some elderly patients initial treatment with one capsule of Madopar 62.5 once or twice daily, increasing by one capsule every third or fourth day may suffice. Patients who experience fluctuations in response may also benefit from administration of smaller, more frequent doses using Madopar 62.5.

#### Contra-indications

Narrow-angle glaucoma; severe psychoneuroses or psychoses. It should not be given in conjunction with monoamine oxidase inhibitors or within two weeks of their withdrawal; to patients under 25 years of age; to pregnant women; or to patients who have a history of, or who may be suffering from, a malignant melanoma.

#### Precautions

Drugs which interfere with central amine mechanisms should be avoided. Endocrine, renal, pulmonary or cardiovascular disease, hepatic disorder, peptic ulcer, osteoporosis, sympathomimetic drugs, antihypertensive drugs. Patients who improve on Madopar therapy should be advised to resume normal activities gradually as rapid mobilisation may increase the risk of injury.

#### Side-effects

Nausea and vomiting; cardiovascular disturbances; psychiatric disturbances; involuntary movements.

#### Packings

Madopar 62.5 capsules, Madopar 125 capsules and Madopar 250 capsules in packings of 100.

#### Licence Numbers

0031/0125 (Madopar 62.5 capsules); 0031/0073 (Madopar 125 capsules) 0031/0074 (Madopar 250 capsules)

#### Basic NHS Cost

Madopar capsules 62.5 £3.17 per 100.  
Madopar capsules 125 £5.72 per 100  
Madopar capsules 250 £10.23 per 100

#### References

1. Caird, F.I., and Williamson, J. Lancet, 1978, i, 986
2. Godwin-Austen, R.B. Postgrad. med. J., 1977, 53, 729
3. Stern, G.M., and Lees, A.J. Practitioner, 1977, 219, 537



Roche Products Limited, PO Box 8  
Welwyn Garden City, Hertfordshire AL7 3AY  
Madopar is a trade mark.

# Madopar 250, 125 and now 62.5

levodopa plus benserazide

# CELLOLITE<sup>TM</sup>


## SURGICAL SPONGES

CELLOLITE<sup>TM</sup> is a white, synthetic, X-Ray detectable sponge designed to overcome all the drawbacks of conventional absorbent materials.

The main characteristics of CELLOLITE<sup>TM</sup> — its extreme softness and high degree of conformability, its rapid wicking rate and high absorbency capacity, its overall X-Ray opacity and fibre-free nature, all serve to ensure that CELLOLITE<sup>TM</sup> is the only really safe and efficient sponge for Neurosurgery.

In short, no other material can match the properties of CELLOLITE<sup>TM</sup>.

Why struggle on using the same old fibrous patty when you can take a giant step forward with CELLOLITE<sup>TM</sup>? In these days of Space Age surgical techniques why 'make do' with conventional patties?



Use CELLOLITE<sup>TM</sup> Surgical Sponges, the product born out of Space Age technology, and benefit from the superior properties of a sponge with the needs of the Twenty-first Century in mind.

Benefit from the softness and non-abrasive character, the overall X-Ray opacity possible due to 'state of the art' encapsulation of Barium Sulphate particles chemically bonded to the sponge, and, so important in delicate surgery, the fibre-free nature of CELLOLITE<sup>TM</sup> which guarantees that no fibres can be shed into the wound, virtually eliminating the risk of granulomas etc. which are a hazard when using conventional patties.

What other product can offer so much?

Use CELLOLITE<sup>TM</sup> the ideal Neurosurgical Sponge.

 Service to Hospitals

**Smith & Nephew-Southalls Limited**

Alum Rock Rd, Birmingham B8 3DY Telephone: 021-327-0204 Telex: 338340



# Remembering Henry

Edited by Stephen Lock and Heather Windle

*A man of stature—in all ways—Henry Miller occupied a large part in many people's lives and his death in 1976 left a large gap. Though a neurologist of world renown he was best known in the North-East, where he spent most of his life, and where, for the last eight years of it, he was Vice-Chancellor of the University of Newcastle upon Tyne. A cross-section of his many friends and colleagues have contributed their reminiscences to **Remembering Henry** and, as each person saw him from a different angle, those who did not know him will find that the whole man gradually comes to life. Professor John Walton has written the introduction, three of Henry Miller's best-known articles are included (writing was his first interest after neurology), and there is a bibliography of his prolific publications. A fitting tribute, **Remembering Henry** may fill some of the gaps for those who have stayed behind. Profits from the book will be given to the Henry Miller Memorial Appeal.*

Demy Octavo  
Paperback  
166 pages

ISBN 0 7279 0027 7

Price: Inland £3.00; Overseas US\$7.50, including postage  
(Members of the BMA may purchase this book at the special price of:  
Inland £2.50; Overseas US\$6.25)

**ORDER YOUR COPY NOW**

From: The Publisher, BRITISH MEDICAL JOURNAL,  
BMA House, Tavistock Square, London WC1H 9JR